Target Name: MIR942
NCBI ID: G100126331
Review Report on MIR942 Target / Biomarker Content of Review Report on MIR942 Target / Biomarker
Other Name(s): microRNA 942 | hsa-mir-942 | MIRN942 | mir-942 | MicroRNA 942 | hsa-miR-942-3p | hsa-miR-942-5p

Introduction to MIR942, A Potential Drug Target

MIR942, also known as microRNA 942, is a small non-coding RNA molecule that has gained significant attention in recent years as a potential drug target and biomarker for various diseases. This article will explore the role of MIR942 in different physiological processes and its potential applications in medicine.

The Role of MIR942 in Physiology

MicroRNAs are short RNA sequences that regulate gene expression by binding to messenger RNA (mRNA) molecules and inhibiting their translation or promoting their degradation. MIR942, specifically, has been found to play a crucial role in diverse physiological processes, including cell proliferation, apoptosis, and differentiation.

In cancer research, MIR942 has been shown to function as both an oncogene and a tumor suppressor depending on the type of cancer and the cellular context. For instance, in breast cancer, MIR942 is upregulated and promotes tumor growth by inhibiting certain tumor suppressor genes. In contrast, in colorectal cancer, MIR942 downregulation has been observed, leading to increased cancer cell proliferation and invasiveness.

Furthermore, MIR942 has been implicated in neuronal development and function. Studies have suggested its involvement in the regulation of neurogenesis, neuronal migration, and synaptic plasticity. Dysregulation of MIR942 has been linked to neurodevelopmental disorders such as autism and neurodegenerative diseases like Alzheimer's.

MIR942 as a Potential Drug Target

Given its central role in various disease processes, MIR942 presents itself as a promising target for drug development. Targeting MIR942 with specific inhibitors, known as anti-miRs, could potentially disrupt disease-associated pathways and provide therapeutic benefits.

In cancer treatment, designing anti-miR molecules that can selectively inhibit the activity of MIR942 in tumor cells could hinder tumor growth and metastasis. The use of these inhibitors may also enhance the efficacy of existing cancer therapies by sensitizing cancer cells to treatment.

In neurodegenerative diseases, where dysregulation of MIR942 is observed, developing drugs that modulate the expression of MIR942 may have the potential to slow down or halt the progression of these disorders. By restoring the balance of MIR942, it may be possible to mitigate the pathological effects seen in Alzheimer's and other neurodegenerative diseases.

MIR942 as a Biomarker

Apart from its therapeutic potential, MIR942 also shows promise as a biomarker for various diseases. Biomarkers are measurable indicators that reflect the presence or progression of a disease and can be used for disease diagnosis, prognosis, and monitoring treatment response.

In cancer diagnosis, altered expression levels of MIR942 have been detected in various cancer types, including breast, colorectal, lung, and gastric cancers. These aberrant expression patterns make MIR942 a potential biomarker for early cancer detection and monitoring disease progression.

In neurological disorders, evidence suggests that MIR942 could serve as a biomarker for diseases like Alzheimer's and Parkinson's, offering a non-invasive method to diagnose these conditions in their early stages and track disease progression. Identifying biomarkers like MIR942 is crucial for developing targeted therapies and improving patient outcomes.

The Challenges Ahead

While the potential of MIR942 as a drug target and biomarker is exciting, several challenges lie ahead in translating this potential into clinical practice.

One significant challenge is the development of safe and effective delivery systems for anti-miR inhibitors or modulators of MIR942 expression. These delivery systems need to ensure the specific and efficient delivery of the therapeutic agent to the target tissues while minimizing off-target effects and unwanted immune responses.

Additionally, the validation of MIR942 as a biomarker requires large-scale clinical studies to establish its sensitivity, specificity, and reliability. Standardized protocols for sample collection, processing, and quantification of MIR942 need to be established to ensure accurate and reproducible results across different laboratories and clinical settings.


MIR942 is emerging as a promising drug target and biomarker in various diseases. Its involvement in physiological processes and dysregulation in diseases make it an attractive target for therapeutic interventions. The development of effective delivery systems and rigorous clinical validation are essential steps towards harnessing the therapeutic and diagnostic potential of MIR942. With further research and advancements, MIR942 could pave the way for personalized medicine and improved patient outcomes in the future.

Protein Name: MicroRNA 942

The "MIR942 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR942 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

MIR943 | MIR944 | MIR95 | MIR96 | MIR98 | MIR99A | MIR99AHG | MIR99B | MIRLET7 | MIRLET7A1 | MIRLET7A2 | MIRLET7A3 | MIRLET7B | MIRLET7BHG | MIRLET7C | MIRLET7D | MIRLET7E | MIRLET7F1 | MIRLET7F2 | MIRLET7G | MIRLET7I | MIS12 | MIS12 complex | MIS18A | MIS18A-AS1 | MIS18BP1 | MISFA | MISP | MISP3 | MITD1 | MITF | Mitochondrial complex I assembly complex | Mitochondrial import inner membrane translocase 23 (TIM23) complex | Mitochondrial inner membrane protease complex | Mitochondrial membrane ATP synthase | Mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) | Mitochondrial pyruvate carrier complex (MPC) | Mitochondrial RNA processing endoribonuclease | Mitofilin Complex | Mitofusin | Mitogen-Activated Protein Kinase | Mitogen-activated protein kinase (JNK) | Mitogen-Activated Protein Kinase (MAP Kinase)-Activated Protein Kinase | Mitogen-Activated Protein Kinase Kinase Kinase (MAP3K) | Mitogen-activated protein kinase p38 (MAPK p38) | MITRAC complex | MIX23 | MIXL1 | MKI67 | MKKS | MKLN1 | MKLN1-AS | MKNK1 | MKNK1-AS1 | MKNK2 | MKRN1 | MKRN2 | MKRN2OS | MKRN3 | MKRN4P | MKRN7P | MKRN9P | MKS1 | MKX | MLANA | MLC1 | MLEC | MLF1 | MLF1-DT | MLF2 | MLH1 | MLH3 | MLIP | MLIP-AS1 | MLKL | MLLT1 | MLLT10 | MLLT10P1 | MLLT11 | MLLT3 | MLLT6 | MLN | MLNR | MLPH | MLST8 | MLX | MLXIP | MLXIPL | MLYCD | MMAA | MMAB | MMACHC | MMADHC | MMADHC-DT | MMD | MMD2 | MME | MMEL1 | MMGT1 | MMP